Overview

• Karolinska Institutet has developed engineered extracellular vesicles (EVs) that efficiently deliver therapeutic proteins and RNA into cells, overcoming key delivery barriers.
• The method incorporates bacterial inteins and viral fusogenic proteins to enhance endosomal escape and precise intracellular release of therapeutic cargo.
• Preclinical studies demonstrated successful delivery of genome-editing tools, including Cre recombinase and CRISPR/Cas9, in cells and mouse models.
• The engineered EVs achieved targeted delivery to brain regions in mice, demonstrating potential for treating neurological disorders like Huntington's disease.
• Researchers also showed the platform's ability to mitigate systemic inflammation, highlighting its versatility for addressing diverse medical conditions.